Peri-Implant Soft Tissue Augmentation Using a Free Connective Tissue Graft With an Epithelial Collar

Application of a Free Connective Tissue Graft With an Epithelial Collar for Peri-Implant Soft Tissue Augmentation in Patients With Soft Tissue Deficiency Around Dental Implants

A prospective randomized interventional clinical trial (RCT) with a parallel-group design is planned. The study sample will include 32 patients randomly allocated into two groups according to the surgical intervention performed. In the first group, a free connective tissue graft with an epithelial collar will be used. In the second group, a free connective tissue graft without an epithelial collar will be used. In the postoperative period, assessment of changes in the width of keratinized mucosa, soft tissue thickness, pain severity, postoperative swelling, and patient quality of life will be performed.

Study Overview

Detailed Description

The aim of this study is to perform a comparative analysis of the effectiveness of free connective tissue grafts with and without an epithelial collar for peri-implant soft tissue augmentation. Examination and treatment of patients will be carried out at the Department of Oral Surgery of the E.V. Borovsky Institute of Dentistry, Sechenov University.

The study population will include patients with bounded or distal edentulous defects of the upper or lower jaw combined with soft tissue thickness deficiency around dental implants (<2 mm), requiring peri-implant soft tissue augmentation using a free connective tissue graft.

All patients will be randomly allocated into two groups according to the surgical intervention method. In the first group (n=16), a free connective tissue graft without an epithelial collar will be used, while in the second group (n=16), a free connective tissue graft with an epithelial collar will be used. The groups will be comparable in terms of age and sex characteristics.

Patient randomization will be performed intraoperatively as follows: after dental implant placement and preparation of the recipient site, an envelope containing the randomly assigned treatment method will be opened. Patients in both groups will undergo dental implant placement according to the standard surgical protocol combined with peri-implant soft tissue augmentation.

A mucosal incision will be performed followed by elevation of a mucoperiosteal flap, preparation of the implant bed, and placement of the dental implant. Subsequently, the recipient site will be prepared and a free connective tissue graft harvested from the maxillary tuberosity or palatal area. Depending on the allocated group, a graft with or without an epithelial collar will be used. The graft will be fixed to the mucoperiosteal flap, followed by tension-free wound closure, while the donor site will be closed primarily.

In the postoperative period, standard antibacterial and anti-inflammatory therapy combined with topical antiseptic agents will be prescribed.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Moscow, Russia
        • I.M. Sechenov First Moscow State Medical University (Sechenov University)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

  1. Written informed consent for participation in the study;
  2. Age between 18 and 45 years;
  3. Bounded edentulous defects of the upper or lower jaw involving 1-2 teeth combined with soft tissue thickness deficiency around dental implants (<2 mm);
  4. Teeth without periodontal pathology, with probing depth not exceeding 3 mm throughout the gingival sulcus;
  5. Satisfactory level of oral hygiene;
  6. Absence of systemic diseases in the stage of exacerbation or decompensation.

Non-inclusion criteria:

  1. Patients who previously underwent connective tissue graft harvesting from the same donor site;
  2. Patients with impacted third molars in the donor site area;
  3. Presence of concomitant diseases in the stage of exacerbation or decompensation;
  4. Patients with malignant neoplasms, as well as patients who underwent radiation therapy or chemotherapy within the previous 5 years;
  5. Patients with a smoking history of more than 10 years.

Exclusion Criteria:

  1. Patient refusal to continue participation in the study;
  2. Pregnant or breastfeeding women;
  3. Patients with coagulation disorders (hemophilia, von Willebrand disease, or anticoagulant therapy);
  4. Patients with diseases affecting soft tissue healing processes (insulin-dependent diabetes mellitus).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: first group
Patients will receive a free connective tissue graft without an epithelial collar
  1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, preparation of the implant bed and placement of the dental implant according to the standard protocol.
  2. Formation of the recipient site in the vestibular area.
  3. Harvesting of free connective tissue graft from the maxilla tuberosity area or palate and its adaptation to the recipient site.
  4. Fixation of the graft to the vestibular mucosal-periosteal flap and tight suturing of the wound in the recipient area.
  5. Suturing of the wound in the donor site.
Experimental: second group
Patients will receive a free connective tissue graft with epithelial collar
  1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, preparation of the implant bed and placement of the dental implant according to the standard protocol.
  2. Formation of the recipient site in the vestibular area.
  3. Harvesting of free connective tissue graft with epithelial strip from the maxilla tuberosity area or palate and its adaptation to the recipient site.
  4. Fixation of the graft to the vestibular mucosal-periosteal flap and tight suturing of the wound in the recipient area.
  5. Suturing of the wound in the donor site.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Width of Keratinized Mucosa
Time Frame: Day 90 compared to the 0th day (initial value)
Measurements will be performed using optical impressions obtained with the Primescan intraoral scanner (Dentsply/Sirona) or conventional impressions followed by digital scanning before surgery and on postoperative day 90. Subsequently, STL files will be superimposed using GOM Inspect software, and contour changes will be assessed at three equidistant points.
Day 90 compared to the 0th day (initial value)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Width of Keratinized Mucosa
Time Frame: Day 180 compared to the 0th day (initial value)
Measurements will be performed using optical impressions obtained with the Primescan intraoral scanner (Dentsply/Sirona) or conventional impressions followed by laboratory scanning before surgery and on postoperative day 180. Subsequently, STL files will be superimposed using GOM Inspect software, and contour changes will be assessed at three equidistant points.
Day 180 compared to the 0th day (initial value)
Assessment of Scar Formation According to the Modified Scar Index (MSI)
Time Frame: Day 90 compared to the 0th day (initial value)
Assessment of postoperative soft tissue scar quality around dental implants is performed using the Modified Scar Index (MSI) according to Mombelli et al., based on the evaluation of five parameters: scar color, scar contour, soft tissue deformity, scar tissue texture, and wound margin separation. Each parameter is assessed using a 3-point scale, where: 0 = optimal tissue condition; 1 = moderate scar changes; 2 = pronounced scar changes. The total MSI score ranges from 0 to 10, with lower scores indicating better clinical outcomes and minimal scar formation. Clinical assessment is performed visually and by palpation, with additional evaluation using clinical photographs when necessary.
Day 90 compared to the 0th day (initial value)
Assessment of Scar Formation According to the Modified Scar Index (MSI)
Time Frame: Day 180 compared to the 0th day (initial value)
Assessment of postoperative soft tissue scar quality around dental implants is performed using the Modified Scar Index (MSI) according to Mombelli et al., based on the evaluation of five parameters: scar color, scar contour, soft tissue deformity, scar tissue texture, and wound margin separation. Each parameter is assessed using a 3-point scale, where: 0 = optimal tissue condition; 1 = moderate scar changes; 2 = pronounced scar changes. The total MSI score ranges from 0 to 10, with lower scores indicating better clinical outcomes and minimal scar formation. Clinical assessment is performed visually and by palpation, with additional evaluation using clinical photographs when necessary.
Day 180 compared to the 0th day (initial value)
Assessment of Pain Severity
Time Frame: 4 hours compared to the 0th day (initial value)
Assessment of pain severity is performed postoperatively using patient questionnaires, where: 0 = no pain; 1-2 = mild pain; 2-3 = moderate pain; 4-5 = moderately severe pain; 6-7 = severe pain; 8-10 = unbearable pain.
4 hours compared to the 0th day (initial value)
Assessment of Pain Severity
Time Frame: Day 1 compared to the 0th day (initial value)
Assessment of pain severity is performed postoperatively using patient questionnaires, where: 0 = no pain; 1-2 = mild pain; 2-3 = moderate pain; 4-5 = moderately severe pain; 6-7 = severe pain; 8-10 = unbearable pain.
Day 1 compared to the 0th day (initial value)
Assessment of Pain Severity
Time Frame: Day 3 compared to the 0th day (initial value)
Assessment of pain severity is performed postoperatively using patient questionnaires, where: 0 = no pain; 1-2 = mild pain; 2-3 = moderate pain; 4-5 = moderately severe pain; 6-7 = severe pain; 8-10 = unbearable pain.
Day 3 compared to the 0th day (initial value)
Assessment of Pain Severity
Time Frame: Day 5 compared to the 0th day (initial value)
Assessment of pain severity is performed postoperatively using patient questionnaires, where: 0 = no pain; 1-2 = mild pain; 2-3 = moderate pain; 4-5 = moderately severe pain; 6-7 = severe pain; 8-10 = unbearable pain.
Day 5 compared to the 0th day (initial value)
Assessment of Pain Severity
Time Frame: Day 7 compared to the 0th day (initial value)
Assessment of pain severity is performed postoperatively using patient questionnaires, where: 0 = no pain; 1-2 = mild pain; 2-3 = moderate pain; 4-5 = moderately severe pain; 6-7 = severe pain; 8-10 = unbearable pain.
Day 7 compared to the 0th day (initial value)
Assessment of Postoperative Swelling Severity
Time Frame: Day 1 compared to the 0th day (initial value)
Assessment of collateral soft tissue swelling compared with adjacent tissues is performed using the following scale: 0 = no swelling; 1 = moderate swelling; 2 = severe swelling.
Day 1 compared to the 0th day (initial value)
Assessment of Postoperative Swelling Severity
Time Frame: Day 3 compared to the 0th day (initial value)
Assessment of collateral soft tissue swelling compared with adjacent tissues is performed using the following scale: 0 = no swelling; 1 = moderate swelling; 2 = severe swelling.
Day 3 compared to the 0th day (initial value)
Assessment of Postoperative Swelling Severity
Time Frame: Day 5 compared to the 0th day (initial value)
Assessment of collateral soft tissue swelling compared with adjacent tissues is performed using the following scale: 0 = no swelling; 1 = moderate swelling; 2 = severe swelling.
Day 5 compared to the 0th day (initial value)
Assessment of Postoperative Swelling Severity
Time Frame: Day 7 compared to the 0th day (initial value)
Assessment of collateral soft tissue swelling compared with adjacent tissues is performed using the following scale: 0 = no swelling; 1 = moderate swelling; 2 = severe swelling.
Day 7 compared to the 0th day (initial value)
Assessment of Bleeding
Time Frame: Day 1 compared to the 0th day (initial value)
Assessment of the presence of a blood taste in the mouth is performed using the following scale: 0 = no blood taste; 1 = intermittent blood taste; 2 = constant blood taste.
Day 1 compared to the 0th day (initial value)
Assessment of Bleeding
Time Frame: Day 3 compared to the 0th day (initial value)
Assessment of the presence of a blood taste in the mouth is performed using the following scale: 0 = no blood taste; 1 = intermittent blood taste; 2 = constant blood taste.
Day 3 compared to the 0th day (initial value)
Assessment of Bleeding
Time Frame: Day 5 compared to the 0th day (initial value)
Assessment of the presence of a blood taste in the mouth is performed using the following scale: 0 = no blood taste; 1 = intermittent blood taste; 2 = constant blood taste.
Day 5 compared to the 0th day (initial value)
Assessment of Bleeding
Time Frame: Day 7 compared to the 0th day (initial value)
Assessment of the presence of a blood taste in the mouth is performed using the following scale: 0 = no blood taste; 1 = intermittent blood taste; 2 = constant blood taste.
Day 7 compared to the 0th day (initial value)
Assessment of Analgesic Intake
Time Frame: Day 1 compared to the 0th day (initial value)
Assessment of the number of Nimesulide 100 mg tablets taken per day.
Day 1 compared to the 0th day (initial value)
Assessment of Analgesic Intake
Time Frame: Day 3 compared to the 0th day (initial value)
Assessment of the number of Nimesulide 100 mg tablets taken per day.
Day 3 compared to the 0th day (initial value)
Assessment of Analgesic Intake
Time Frame: Day 5 compared to the 0th day (initial value)
Assessment of the number of Nimesulide 100 mg tablets taken per day.
Day 5 compared to the 0th day (initial value)
Assessment of Analgesic Intake
Time Frame: Day 7 compared to the 0th day (initial value)
Assessment of the number of Nimesulide 100 mg tablets taken per day.
Day 7 compared to the 0th day (initial value)
Quality of Life Assessment According to OHIP-14
Time Frame: Day 0 (initial value)
Assessment of patient quality of life is performed using a questionnaire consisting of 10 questions. The severity of each parameter should be rated from 0 to 4 points, where "0" = absence of the symptom and "4" = symptom is strongly pronounced.
Day 0 (initial value)
Quality of Life Assessment According to OHIP-14
Time Frame: Day 7 compared to the 0th day (initial value)
Assessment of patient quality of life is performed using a questionnaire consisting of 10 questions. The severity of each parameter should be rated from 0 to 4 points, where "0" = absence of the symptom and "4" = symptom is strongly pronounced.
Day 7 compared to the 0th day (initial value)
Quality of Life Assessment According to OHIP-14
Time Frame: Day 90-93 compared to the 0th day (initial value)
Assessment of patient quality of life is performed using a questionnaire consisting of 10 questions. The severity of each parameter should be rated from 0 to 4 points, where "0" = absence of the symptom and "4" = symptom is strongly pronounced.
Day 90-93 compared to the 0th day (initial value)
Quality of Life Assessment According to OHIP-14
Time Frame: Day 180-186 compared to the 0th day (initial value)
Assessment of patient quality of life is performed using a questionnaire consisting of 10 questions. The severity of each parameter should be rated from 0 to 4 points, where "0" = absence of the symptom and "4" = symptom is strongly pronounced.
Day 180-186 compared to the 0th day (initial value)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Igor P Ashurko, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2024

Primary Completion (Estimated)

June 20, 2026

Study Completion (Estimated)

August 20, 2026

Study Registration Dates

First Submitted

May 29, 2026

First Submitted That Met QC Criteria

May 29, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

May 29, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Soft Tissue Atrophy

Clinical Trials on Free connective tissue graft without an epithelial collar

Subscribe